Clinical impact of synchronous and metachronous malignancies in patients with oral cancer.
In a retrospective study, 20 of 379 patients (5.2%) with cancer of the oral cavity developed second malignant tumors (SMT) at various sites. The diagnosis of SMT was made with an average delay of 49.2 months. In view of the increasing incidence of SMT after curative treatment of oral cancer, the use of chemopreventive drugs should be considered.
Eckardt
A
A
Department of Oral and Maxillofacial Surgery, Hanover Medical School, Germany.
D000230:Adenocarcinoma / Q000453:epidemiology / Q000628:therapy; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002294:Carcinoma, Squamous Cell / Q000453:epidemiology / Q000628:therapy*; D003110:Colonic Neoplasms / Q000453:epidemiology / Q000628:therapy; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D015994:Incidence; D008175:Lung Neoplasms / Q000209:etiology; D008297:Male; D008875:Middle Aged; D009062:Mouth Neoplasms / Q000453:epidemiology / Q000628:therapy*; D009378:Neoplasms, Multiple Primary / Q000453:epidemiology / Q000401:mortality / Q000628:therapy*; D016609:Neoplasms, Second Primary / Q000453:epidemiology / Q000517:prevention & control*; D010610:Pharyngeal Neoplasms / Q000453:epidemiology / Q000628:therapy; D012189:Retrospective Studies; D012907:Smoking / Q000009:adverse effects; D016019:Survival Analysis; D015996:Survival Rate